Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 462

1.

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.

Japour AJ, Lertora JJ, Meehan PM, Erice A, Connor JD, Griffith BP, Clax PA, Holden-Wiltse J, Hussey S, Walesky M, Cooney E, Pollard R, Timpone J, McLaren C, Johanneson N, Wood K, Booth D, Bassiakos Y, Crumpacker CS.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):235-46.

PMID:
8898668
2.

The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.

Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.

Clin Ther. 1999 Nov;21(11):1853-63.

PMID:
10890257
3.

Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.

Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, Diaz C, Yogev R, McKinney RE Jr, Abrams EJ, Mofenson LM.

Pediatrics. 1999 May;103(5):e62.

PMID:
10224206
4.

Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.

Mobley JE, Pollard RB, Schrader S, Adler MH, Kelleher T, McLaren C.

AIDS. 1999 Jul 30;13(11):F87-93.

PMID:
10449279
5.

Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.

Kline MW, Fletcher CV, Federici ME, Harris AT, Evans KD, Rutkiewicz VL, Shearer WT, Dunkle LM.

Pediatrics. 1996 Jun;97(6 Pt 1):886-90.

PMID:
8657531
6.

Zidovudine and lamivudine: results of phase III studies.

Staszewski S.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S57.

PMID:
8595510
7.

A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.

Gatell JM, Leal M, Mallolas J, Vidal C, Pumarola T, Parra R, Padró S, Caruz A, Falgueras T, Rey C, Sánchez-Quijano A, Torres Y, Lissen E, Jiménez de Anta MT, Soriano E.

Antivir Ther. 1996 Apr;1(2):105-12.

PMID:
11321180
8.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
10.

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC.

Ann Intern Med. 1996 Jun 15;124(12):1039-50.

PMID:
8633817
11.

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

Vidal C, García F, Gatell JM, Leal M, Clotet B, Pumarola T, Miró JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):55-60.

PMID:
9732070
12.
14.

A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.

McKinney RE Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA.

J Pediatr. 1998 Oct;133(4):500-8.

PMID:
9787687
15.

A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.

Mole L, Schmidgall D, Holodniy M.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):260-5.

PMID:
11464145
16.

Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients.

Raffi F, Reliquet V, Auger S, Besnier JM, Chennebault JM, Billaud E, Michelet C, Perre P, Lafeuillade A, May T, Billaudel S.

AIDS. 1998 Oct 22;12(15):1999-2005.

PMID:
9814868
17.

Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy. The AI454-147 Team.

Kazatchkine MD, Van PN, Costagliola D, Mohammed AS, Ledeine JM, Troccaz M, Belec L.

J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):418-24.

PMID:
11035612
18.

Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.

Monno L, Cargnel A, Soranzo ML, Chirianni A, Ferraro T, Di Stefano M, Angarano G.

Antivir Ther. 1999;4(4):195-202.

PMID:
10723498
19.

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.

Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT.

Ann Intern Med. 1997 Jun 15;126(12):929-38.

PMID:
9182469
20.

A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.

Ruxrungtham K, Kroon ED, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, van Leeuwen R, Weverling GJ, Kunanusont C, Lange JM, Cooper DA, Phanuphak P.

AIDS. 2000 Jul 7;14(10):1375-82.

PMID:
10930152

Supplemental Content

Support Center